Therapeutic Asset Ratings
209 results matching 1 filter
128,677 assets · 8,673 sponsors · 3,127 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Fluzoparib
Non-small Cell Lung Cancer
Sun Yat-sen University
P2
CC
(46)
gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-15*07 (86.9%)--(IGHD) -IGHJ1*01(90.9%), CDR-IMGT [8.10.9] (26-33.51-60.99-107))(1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1K120, CH3 D12, L14 (CH1 K120 (215) (119-216),hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV2-24*01 (90.0%)-IGKJ2*01 (100%), CDR-IMGT [11.3.10] (27-37.55-57.94-103)) (1'-113') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa
non-small cell lung carcinoma
AstraZeneca
P2
CC
(46)
GLOBO H-CRM197 VACCINE
Non-small Cell Lung Cancer
OBI Pharma, Inc
P2
CC
(46)
Gumarontinib
non-small cell lung carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
CC
(46)
Herombopag Olamine Tablets
non-small cell lung carcinoma
Henan Cancer Hospital
P2
CC
(46)
Idarubicine
non-small cell lung carcinoma
Second Affiliated Hospital of Guangzhou Medical University
P2
CC
(46)
Kl-A167
non-small cell lung carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
P2
CC
(46)
Lbl-007
non-small cell lung carcinoma
BeiGene
P2
CC
(46)
Saponin-Based Immunoadjuvant Obi-821
Non-small Cell Lung Cancer
OBI Pharma, Inc
P2
CC
(46)
Shr-A2009 ; Aumolertinib
non-small cell lung carcinoma
Three Gorges Hospital of Chongqing University
P2
CC
(46)
SUTETINIB
non-small cell lung carcinoma
Teligene US
P2
CC
(46)
Imm-6-415
non-small cell lung carcinoma
Immuneering Corporation
P1/2
CC
(42)
Aguix
non-small cell lung carcinoma
Dana-Farber Cancer Institute
P1/2
CC
(40)
Amt-116 Car-T Cells
non-small cell lung carcinoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
P1/2
CC
(40)
Amt-253 Car-T Cells
non-small cell lung carcinoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
P1/2
CC
(40)
azd6750
non-small cell lung carcinoma
AstraZeneca
P1/2
CC
(40)
Bl-M02D1
non-small cell lung carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
P1/2
CC
(40)
BMS-986442
non-small cell lung carcinoma
Bristol-Myers Squibb
P1/2
CC
(40)
bnt326
non-small cell lung carcinoma
BioNTech SE
P1/2
CC
(40)
bnt327
non-small cell lung carcinoma
BioNTech SE
P1/2
CC
(40)
Bpi-361175
non-small cell lung carcinoma
Xcovery Holdings, Inc.
P1/2
CC
(40)
Camizestrant
non-small cell lung carcinoma
AstraZeneca
P1/2
CC
(40)
cts2190 capsules
non-small cell lung carcinoma
CytosinLab Therapeutics Co., Ltd.
P1/2
CC
(40)
Gecacitinib
non-small cell lung carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
P1/2
CC
(40)
gen1107
non-small cell lung carcinoma
Genmab
P1/2
CC
(40)
Showing 101 to 125 of 209 assets
Previous
Page 5 of 9
Next
